Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 130
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Ann Hematol ; 103(3): 905-915, 2024 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-38057424

RESUMEN

The study analysed the clinical characteristics, treatment approaches, and survival outcomes of 97 consecutive patients with orbital lymphoma (OL) over a 25-year period at. The median age of the patients was 57.6 years, and 59.8% (n = 58) were male. Marginal zone lymphoma constitutes the most prevalent subtype, accounting for 67% of cases, whereas other common subtypes include diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, Burkitt lymphoma, and T-cell lymphomas. Unilateral involvement was observed in the majority of cases (72.3%). Common clinical presentations included mass (30.9%), swelling (26.8%), and epiphora (11.3%). Of the patients, 7.2% received rituximab alone, 14.4% received radiotherapy alone, 48.5% received chemotherapy, 27.8% received radiotherapy plus rituximab, 22.7% received radiotherapy plus chemotherapy, and 5.2% underwent surgery as the first-line treatment. During a median follow-up of 4.3 years, 15.5% of patients experienced relapse or disease progression. The 5-year and 10-year progression-free survival rates were 84.1% and 79.1%, respectively. This study contributes to our understanding of OLs and provides a foundation for further investigations in this field. Male gender, presence of B symptoms, advanced stage, secondary orbital lymphoma, aggressive histological subtype, and elevated serum lactate dehydrogenase levels were associated with poorer (either inferior or worse) progression-free survival.


Asunto(s)
Linfoma de Células B de la Zona Marginal , Linfoma Folicular , Linfoma , Neoplasias Orbitales , Humanos , Masculino , Adulto , Persona de Mediana Edad , Femenino , Rituximab , Pronóstico , Recurrencia Local de Neoplasia , Neoplasias Orbitales/epidemiología , Neoplasias Orbitales/terapia , Linfoma de Células B de la Zona Marginal/diagnóstico , Linfoma de Células B de la Zona Marginal/terapia , Linfoma de Células B de la Zona Marginal/patología , Estudios Retrospectivos
2.
Int Ophthalmol ; 44(1): 307, 2024 Jul 02.
Artículo en Inglés | MEDLINE | ID: mdl-38955894

RESUMEN

PURPOSE: To review long-term outcomes of circumscribed choroidal hemangioma (CCH). METHODS: Hospital charts of all CCH cases diagnosed from 2008 to 2019 were retrospectively reviewed. RESULTS: All 172 patients were managed with either observation, transpupillary thermotherapy, argon laser photocoagulation, photodynamic therapy, plaque brachytherapy or stereotactic radiosurgery. The most common 3 modes of management were clinical observation (30.2%), transpupillary thermotherapy (52.9%) and argon laser photocoagulation (8.7%). Median follow-up time was 10 months (range: 3, 160). Anatomical outcomes were stable in 87.1% of observation group and improved in 60.5% of thermotherapy group. Quantified optical coherence tomography angiography findings showed statistical differences in vascular and perfusion densities in fellow eyes of hemangioma patients. CONCLUSION: Circumscribed choroidal hemangioma can be treated in various ways. Transpupillary thermotherapy is an anatomically effective treatment in selected cases. The diagnosis of CCH may have vascular implications in fellow eyes of the patients.


Asunto(s)
Neoplasias de la Coroides , Angiografía con Fluoresceína , Hemangioma , Centros de Atención Terciaria , Tomografía de Coherencia Óptica , Agudeza Visual , Humanos , Neoplasias de la Coroides/terapia , Neoplasias de la Coroides/diagnóstico , Femenino , Masculino , Estudios Retrospectivos , Persona de Mediana Edad , Tomografía de Coherencia Óptica/métodos , Angiografía con Fluoresceína/métodos , Adulto , Centros de Atención Terciaria/estadística & datos numéricos , Hemangioma/terapia , Hemangioma/diagnóstico , Anciano , Estudios de Seguimiento , Fotoquimioterapia/métodos , Hipertermia Inducida/métodos , Fondo de Ojo , Adulto Joven , Coroides/patología , Coroides/irrigación sanguínea
3.
Ophthalmic Res ; 66(1): 1230-1244, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37647867

RESUMEN

INTRODUCTION: Uveal melanoma (UM) responds poorly to targeted therapies or immune checkpoint inhibitors. Adenosine monophosphate-activated protein kinase (AMPK) is a pivotal serine/threonine protein kinase that coordinates vital processes such as cell growth. Targeting AMPK pathway, which represents a critical mechanism mediating the survival of UM cells, may prove to be a novel treatment strategy for UM. We aimed to demonstrate the effects of AMPK modulation on UM cells. METHODS: In silico analyses were performed to compare UM and normal melanocyte cells via Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Set Enrichment Analysis (GSEA). The effects of AMPK modulation on cell viability and proliferation in UM cell lines with different molecular profiles (i.e., 92-1, MP46, OMM2.5, and Mel270) were investigated via XTT cell viability and proliferation assays after treating the cells with varying concentrations of A-769662 (AMPK activator) or dorsomorphin (AMPK inhibitor). RESULTS: KEGG/GSEA studies demonstrated that genes implicated in the AMPK signaling pathway were differentially regulated in UM. Gene sets comprising genes involved in AMPK signaling and genes involved in energy-dependent regulation of mammalian target of rapamycin by liver kinase B1-AMPK were downregulated in UM. We observed gradual decreases in the numbers of viable UM cells as the concentration of A-769662 treatment increased. All UM cells demonstrated statistically significant decreases in cell viability when treated with 200 µm A-769662. Moreover, the effects of AMPK inhibition on UM cells were potent, since low doses of dorsomorphin treatment resulted in significant decreases in viabilities of UM cells. The half maximal inhibitory concentration (IC50) values confirmed the potency of dorsomorphin treatment against UM in vitro. CONCLUSION: AMPK may act like a friend or a foe in cancer depending on the context. As such, the current study contributes to the literature in determining the effects of therapeutic strategies targeting AMPK in several UM cells. We propose a new perspective in the treatment of UM. Targeting AMPK pathway may open up new avenues in developing novel therapeutic approaches to improve overall survival in UM.


Asunto(s)
Proteínas Quinasas Activadas por AMP , Melanoma , Humanos , Proteínas Quinasas Activadas por AMP/farmacología , Proteínas Quinasas Activadas por AMP/uso terapéutico , Línea Celular Tumoral , Proliferación Celular , Supervivencia Celular , Melanoma/tratamiento farmacológico , Melanoma/genética
4.
Surg Radiol Anat ; 44(5): 721-725, 2022 May.
Artículo en Inglés | MEDLINE | ID: mdl-35598200

RESUMEN

We report one retinoblastoma patient with dual ophthalmic arteries (also known as "double ophthalmic arteries") arising from the internal carotid artery which fuse with each other inside the orbit. The caudal ophthalmic artery with larger caliber originated from the cavernous segment of internal carotid artery and passed through the superior orbital fissure. The cranial and tiny one arose more cranially from the supraclinoid internal carotid artery and passed through the optic canal. After superselective catheterization, frank anastomosis was shown between two ophthalmic arteries and the central retinal artery arose from the cranial one. To the best of our knowledge, this case is the first observation of a dual ophthalmic artery with cavernous/supracavernous origins fusing with each other proven by superselective ophthalmic angiography. Whether there is an anastomosis between two ophthalmic arteries is important for deciding which artery to be selected for intraarterial treatment. In cases of retinoblastoma, detailed angiographic analysis may be essential to examine the orbital arterial system and to avoid unexpected complications during intraarterial chemotherapy.


Asunto(s)
Neoplasias de la Retina , Retinoblastoma , Arteria Carótida Interna/diagnóstico por imagen , Humanos , Infusiones Intraarteriales , Arteria Oftálmica/diagnóstico por imagen , Neoplasias de la Retina/diagnóstico , Neoplasias de la Retina/tratamiento farmacológico , Retinoblastoma/diagnóstico , Retinoblastoma/terapia
5.
Exp Eye Res ; 212: 108802, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34688623

RESUMEN

Vitreous humor (VH) is not considered as a critical structure in the radiotherapy planning process. In the present study, an experimental animal model was performed to examine the effects of radiotherapy on VH. The right eyes of twelve New Zealand rabbits were irradiated to 60 Gy in 3 fractions in accordance with the scheme used in the treatment of uveal melanoma in our clinic, and contralateral (left) eyes were considered as control. Weekly ophthalmologic examination was performed after irradiation, for three months. At the end of the third month, enucleation and vitreous collection were conducted. The vitreous samples were subjected to metabolomic analyses, ELISA analyses, viscosity measurements, and electron microscopic examination. In control and experimental vitreous samples, 275 different metabolites were identified, and 34 were found to differ significantly between groups. In multivariate analyzes, a clear distinction was observed between control and irradiated vitreous samples. Pathway analysis revealed that nine pathways were affected, and these pathways were mainly related to amino acid metabolism. A significant decrease was observed in the expressions of type II, V, and XI collagens in protein level in the ELISA. There was a non-significant decrease in type IX collagen and viscosity. Electron microscopic examination revealed disrupted collagen fibrillar ultra-structure and dispersed collagen fragments in the experimental vitreous. An intact vitreous is essential for a healthy eye. In this study, we observed that radiation causes changes in the vitreous that may have long-term consequences.


Asunto(s)
Líquidos Corporales/metabolismo , Colágeno/metabolismo , Melanoma/radioterapia , Neoplasias Experimentales , Neoplasias de la Úvea/radioterapia , Cuerpo Vítreo/efectos de la radiación , Animales , Masculino , Melanoma/metabolismo , Melanoma/patología , Conejos , Neoplasias de la Úvea/metabolismo , Neoplasias de la Úvea/patología , Cuerpo Vítreo/diagnóstico por imagen , Cuerpo Vítreo/metabolismo
6.
Pediatr Blood Cancer ; 68(6): e28963, 2021 06.
Artículo en Inglés | MEDLINE | ID: mdl-33720495

RESUMEN

INTRODUCTION: Advanced intraocular retinoblastoma can be cured by enucleation, but spread of retinoblastoma cells beyond the natural limits of the eye is related to a high mortality. Adjuvant therapy after enucleation has been shown to prevent metastasis in children with risk factors for extraocular retinoblastoma. However, histological criteria and adjuvant treatment regimens vary and there is no unifying consensus on the optimal choice of treatment. METHOD: Data on guidelines for adjuvant treatment in European retinoblastoma referral centres were collected in an online survey among all members of the European Retinoblastoma Group (EURbG) network. Extended information was gathered via personal email communication. RESULTS: Data were collected from 26 centres in 17 countries. Guidelines for adjuvant treatment were in place at 92.3% of retinoblastoma centres. There was a consensus on indication for and intensity of adjuvant treatment among more than 80% of all centres. The majority of centres use no adjuvant treatment for isolated focal choroidal invasion or prelaminar optic nerve invasion. Patients with massive choroidal invasion or postlaminar optic nerve invasion receive adjuvant chemotherapy, while microscopic invasion of the resection margin of the optic nerve or extension through the sclera are treated with combined chemo- and radiotherapy. CONCLUSION: Indications and adjuvant treatment regimens in European retinoblastoma referral centres are similar but not uniform. Further biomarkers in addition to histopathological risk factors could improve treatment stratification. The high consensus in European centres is an excellent foundation for a common European study with prospective validation of new biomarkers.


Asunto(s)
Neoplasias de la Retina/terapia , Retinoblastoma/terapia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Quimioterapia Adyuvante/métodos , Niño , Preescolar , Terapia Combinada/métodos , Europa (Continente) , Enucleación del Ojo , Humanos , Pronóstico , Radioterapia Adyuvante/métodos , Neoplasias de la Retina/patología , Retinoblastoma/patología , Factores de Riesgo , Encuestas y Cuestionarios
7.
Ophthalmic Plast Reconstr Surg ; 37(2): e59-e60, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-32618827

RESUMEN

Recurrence of cavernous venous malformation is exceedingly rare. In 1995, a 16-year-old woman was referred for left axial proptosis. Her left visual acuity was 20/200, and there were choroidal folds in the OS. MRI studies showed a well-circumscribed retrobulbar intraconal mass in the left orbit. The tumor was totally removed with intact capsule through a transconjunctival orbitotomy and proved to be a cavernous venous malformation. In 2020, at the age of 41 years and 25 years after the operation, she again presented with left proptosis. Imaging results were very similar to those at first presentation. This tumor was also extirpated in its entirety via an inferior forniceal orbitotomy with the histopathologic diagnosis of a cavernous venous malformation. Her final left visual acuity remained 20/50. Women with orbital cavernous venous malformations, especially those who undergo surgical removal at a relatively young age are advised to have long-term follow up complemented with occasional imaging studies.


Asunto(s)
Exoftalmia , Hemangioma Cavernoso , Neoplasias Orbitales , Adolescente , Adulto , Femenino , Hemangioma Cavernoso/diagnóstico , Hemangioma Cavernoso/cirugía , Humanos , Imagen por Resonancia Magnética , Recurrencia Local de Neoplasia , Órbita , Neoplasias Orbitales/diagnóstico , Neoplasias Orbitales/cirugía
8.
Graefes Arch Clin Exp Ophthalmol ; 256(11): 2225-2231, 2018 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-29961117

RESUMEN

PURPOSE: To assess the effectiveness of intra-arterial chemotherapy (IAC), intravenous chemotherapy (IVC), and their combination in the management of group D retinoblastoma. METHODS: This was a retrospective, interventional, comparative, and non-randomized clinical study, including all eyes with primarily treated group D retinoblastoma managed in a single institution from February 2010 to July 2016. Patient demographics, treatment modality (primary enucleation, intravenous chemotherapy, intra-arterial chemotherapy alone or intravenous, and intra-arterial chemotherapy), additional need for consolidation treatments or intravitreal melphalan (IVM) injections, and follow-up time were recorded. The main outcome measure was ocular survival rate after various treatment modalities. RESULTS: Of 87 eyes of 83 consecutive cases, 9 eyes (10.3%) were primarily enucleated, 37 (42.6%) eyes received IVC, 30 (34.5%) eyes had IAC, and 11 (12.6%) eyes were treated with IVC followed by IAC. After a mean 81.1 ± 75.2 weeks of follow-up, enucleation rates were 56.8% in the IVC group, 23.3% in the IAC group, and 36.6% in the IVC + IAC group (p = 0.021). There was no significant difference of ocular survival estimates among these 3 groups at 2 or 5 years (p = 0.998, p = 0.986). With logistic regression analysis, age; gender; disease laterality; administration of IVM, TTT, or cryotherapy; mean dose of IVM; follow-up time; and number of IAC or IVC cycles were not significantly related to the enucleation rate (p > 0.05 for all variables). CONCLUSIONS: Our experience showed that in group D patients, primary IAC achieved ocular survival in 76.7% of eyes, and less need for local consolidation treatments, whereas following primary IVC ocular survival was 43.2%.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Enucleación del Ojo , Neoplasias de la Retina/terapia , Retinoblastoma/terapia , Carboplatino/uso terapéutico , Niño , Preescolar , Crioterapia , Etopósido/uso terapéutico , Femenino , Humanos , Lactante , Recién Nacido , Infusiones Intraarteriales , Infusiones Intravenosas , Inyecciones Intravítreas , Masculino , Neoplasias de la Retina/tratamiento farmacológico , Neoplasias de la Retina/mortalidad , Neoplasias de la Retina/cirugía , Retinoblastoma/tratamiento farmacológico , Retinoblastoma/mortalidad , Retinoblastoma/cirugía , Estudios Retrospectivos , Tasa de Supervivencia , Vincristina/uso terapéutico
9.
Ophthalmic Plast Reconstr Surg ; 34(3): e77-e79, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29342030

RESUMEN

A 23-year-old woman presented with right-sided painless proptosis that developed in 12 months. MRI studies demonstrated a well-delineated tumorous enlargement of the right lacrimal gland with homogenous signal intensity and compressing the globe. The tumor was removed totally and in 1 piece with the tentative diagnosis of a pleomorphic adenoma. Pathologic examination revealed biphasic neoplastic elements, which were composed of the cartilaginous matrix and small round cell component. Immunohistopathological examination showed positive CD99 staining and negative reaction to S100, panCK, and CD15. The patient then received a total of 64 Gy orbital radiotherapy in 32 fractionations. There has been no recurrence or metastasis during 14 months of follow up. This case showed that mesenchymal chondrosarcoma may arise from the lacrimal gland and must be considered in the differential diagnosis of lacrimal gland tumors in young adults.


Asunto(s)
Neoplasias Óseas/patología , Condrosarcoma Mesenquimal/patología , Neoplasias del Ojo/patología , Aparato Lagrimal/patología , Diagnóstico Diferencial , Femenino , Humanos , Adulto Joven
10.
Orbit ; 37(3): 179-186, 2018 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-29039986

RESUMEN

PURPOSE: To determine the changes in indications for orbital exenteration over 20 years and to assess its impact on patient survival. Evolving techniques of rehabilitation of the orbit in our institution were also evaluated. METHODS: This was a retrospective review of hospital records of patients who underwent orbital exenteration from 1995 to 2015 in a tertiary care center. Data extracted included primary location of the tumor, preoperative treatments, interval between initial diagnosis and exenteration, status of surgical margins, presence of metastatic disease, and postoperative survival. The types of prosthesis utilized over the years were also reviewed. Cox regression analysis was performed for categorical variables. Kaplan-Meier analysis was used to estimate post-exenteration survival. RESULTS: Over a 20-year period, orbital exenteration was performed on 100 orbits of 100 patients. The mean age was 39.4 years (range: 2 months to 90 years). The most common indications among 98 malignant causes were retinoblastoma, squamous cell carcinoma, basal cell carcinoma, extraocular extension of uveal melanoma, and conjunctival melanoma. Postoperative survival was significantly related to age and tumor location but independent from gender, surgical margin, histopathological diagnosis, previous treatment modality, and preoperative interval. In the whole cohort, 1-year and 5-year survival rates were 97% and 84%, respectively. CONCLUSIONS: Exenteration appears to be life-saving in children with orbital extension of retinoblastoma. While patients exenterated for malignant eyelid tumors have the best chance of survival, those with orbital extension of uveal melanoma and adenoid cystic carcinoma of the lacrimal gland have the worst prognosis.


Asunto(s)
Técnicas de Diagnóstico Oftalmológico/tendencias , Neoplasias del Ojo/cirugía , Evisceración Orbitaria , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Supervivencia sin Enfermedad , Neoplasias del Ojo/diagnóstico por imagen , Neoplasias del Ojo/rehabilitación , Femenino , Humanos , Lactante , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Implantes Orbitales , Estudios Retrospectivos , Tasa de Supervivencia
11.
Neuro Endocrinol Lett ; 38(4): 248-254, 2017 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28871709

RESUMEN

Carney Complex (CNC) is a multiple neoplasia syndrome characterized by skin tumors and pigmented lesions, myxomas, and various endocrine tumors. The aim of this case report was to describe a case of CNC with a novel PRKAR1A mutation. A man aged 46 years with a medical history of surgery for cardiac myxomas at the age of 39 was admitted to our hospital because of four newly-developed heart masses. The histologic examination confirmed cardiac myxomas. He had many presentations of CNC such as growth hormone (GH) and prolactin (PRL)-secreting mixed pituitary adenoma, benign thyroid nodule, large-cell calcifying Sertoli cell tumor (LCCST), and superficial angiomyxoma. A bilateral adrenalectomy was performed because the laboratory findings suggested primary pigmented nodular adrenocortical disease (PPNAD). The pathologic examination revealed a focal unilateral PPNAD, unilateral nonpigmented adrenocortical nodule, and bilateral adrenal medullary hyperplasia. Two years after the second cardiac operation, an interatrial septum-derived tumor was detected. An atrial myxoma was confirmed with histologic studies. Based on these findings, the patient was confirmed to have CNC. A novel insertion mutation in the type 1A regulatory subunit of the cAMP-dependent protein kinase A gene (PRKAR1A) in exon 2 was detected in our patient through genetic analysis. The presence of multiple myxomas and endocrine abnormalities should be an indication to physicians to further investigate for CNC. Herein, we described a case of CNC with a novel mutation in exon 2 of the PRKAR1A gene with typical and atypical clinical features.


Asunto(s)
Complejo de Carney/diagnóstico , Subunidad RIalfa de la Proteína Quinasa Dependiente de AMP Cíclico/genética , Neoplasias Cardíacas/genética , Mutación , Mixoma/genética , Complejo de Carney/genética , Complejo de Carney/patología , Neoplasias Cardíacas/patología , Neoplasias Cardíacas/cirugía , Humanos , Masculino , Persona de Mediana Edad , Mixoma/patología , Mixoma/cirugía
12.
Ophthalmic Plast Reconstr Surg ; 33(3S Suppl 1): S125-S127, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-26505233

RESUMEN

The authors report the case of a 4-year-old boy who presented with unilateral ptosis and a mass lesion of palpebral conjunctiva of the left upper eyelid, that had been present for 2 weeks, and had rapidly enlarged. The lesion was salmon colored and was easily distinguished from the conjunctiva. There was no obvious orbital extension in the MRI studies. Excisional biopsy was performed through a conjunctival approach. The histopathology was consistent with embryonal rhabdomyosarcoma. Thoracoabdominal CT scans revealed nodules in both lungs, indicating stage 4 disease. The patient received chemotheraphy and intensity-modulated radiation therapy. Rhabdomyosarcoma confined to the conjunctiva and distant metastasis without orbital involvement is rare. It should be included in the differential diagnosis of any atypical conjunctival mass lesions in children, and histopathology is necessary to establish proper treatment. As the case indicates, detailed systemic evaluation and careful systemic follow up of these patients are mandatory.


Asunto(s)
Conjuntiva/patología , Neoplasias de la Conjuntiva/patología , Neoplasias Pulmonares/secundario , Rabdomiosarcoma Embrionario/secundario , Biopsia , Niño , Diagnóstico Diferencial , Humanos , Neoplasias Pulmonares/diagnóstico , Imagen por Resonancia Magnética , Masculino , Rabdomiosarcoma Embrionario/diagnóstico
13.
Ophthalmology ; 123(4): 898-907, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-26854035

RESUMEN

PURPOSE: To collect comprehensive data on choroidal and ciliary body melanoma (CCBM) in children and to validate hypotheses regarding pediatric CCBM: children younger than 18 years, males, and those without ciliary body involvement (CBI) have more favorable survival prognosis than young adults 18 to 24 years of age, females, and those with CBI. DESIGN: Retrospective, multicenter observational study. PARTICIPANTS: Two hundred ninety-nine patients from 24 ocular oncology centers, of whom 114 were children (median age, 15.1 years; range, 2.7-17.9 years) and 185 were young adults. METHODS: Data were entered through a secure website and were reviewed centrally. Survival was analyzed using Kaplan-Meier analysis and Cox proportional hazards regression. MAIN OUTCOME MEASURES: Proportion of females, tumor-node-metastasis (TNM) stage, cell type, and melanoma-related mortality. RESULTS: Cumulative frequency of having CCBM diagnosed increased steadily by 0.8% per year of age between 5 and 10 years of age and, after a 6-year transition period, by 8.8% per year from age 17 years onward. Of children and young adults, 57% and 63% were female, respectively, which exceeded the expected 51% among young adults. Cell type, known for 35% of tumors, and TNM stage (I in 22% and 21%, II in 49% and 52%, III in 30% and 28%, respectively) were comparable for children and young adults. Melanoma-related survival was 97% and 90% at 5 years and 92% and 80% at 10 years for children compared with young adults, respectively (P = 0.013). Males tended to have a more favorable survival than females among children (100% vs. 85% at 10 years; P = 0.058). Increasing TNM stage was associated with poorer survival (stages I, II, and III: 100% vs. 86% vs. 76%, respectively; P = 0.0011). By multivariate analysis, being a young adult (adjusted hazard rate [HR], 2.57), a higher TNM stage (HR, 2.88 and 8.38 for stages II and III, respectively), and female gender (HR, 2.38) independently predicted less favorable survival. Ciliary body involvement and cell type were not associated with survival. CONCLUSIONS: This study confirms that children with CCBM have a more favorable survival than young adults 18 to 25 years of age, adjusting for TNM stage and gender. The association between gender and survival varies between age groups.


Asunto(s)
Neoplasias de la Coroides/epidemiología , Cuerpo Ciliar/patología , Melanoma/epidemiología , Neoplasias de la Úvea/epidemiología , Adolescente , Niño , Preescolar , Neoplasias de la Coroides/mortalidad , Neoplasias de la Coroides/terapia , Europa (Continente)/epidemiología , Enucleación del Ojo , Femenino , Encuestas Epidemiológicas , Humanos , Masculino , Oncología Médica/organización & administración , Melanoma/mortalidad , Melanoma/terapia , Recurrencia Local de Neoplasia/diagnóstico , Procedimientos Quirúrgicos Oftalmológicos , Oftalmología/organización & administración , Fotoquimioterapia , Radioterapia , Estudios Retrospectivos , Tasa de Supervivencia , Neoplasias de la Úvea/mortalidad , Neoplasias de la Úvea/terapia , Adulto Joven
14.
Clin Exp Rheumatol ; 33(3): 409-410, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25897575

RESUMEN

IgG4-related disease is a systemic fibro-inflammatory disorder mainly affecting the middle-aged and elderly population. IgG4-related orbital disease is very rare in childhood. We present here two children with IgG4-related orbital disease, one of whom responded well to prednisolone treatment while the other one was refractory to most immunosuppressive agents. It is important to treat patients at the early active stage of disease before fibrotic changes predominate. Thus, although rare, increased awareness of IgG4-related orbital disease in childhood may avoid delays in diagnosis and treatment.


Asunto(s)
Enfermedades Autoinmunes/inmunología , Inmunoglobulina G/análisis , Enfermedades Orbitales/inmunología , Adolescente , Enfermedades Autoinmunes/diagnóstico , Enfermedades Autoinmunes/tratamiento farmacológico , Biomarcadores/análisis , Biopsia , Niño , Diagnóstico Precoz , Femenino , Glucocorticoides/uso terapéutico , Humanos , Inmunohistoquímica , Inmunosupresores/uso terapéutico , Enfermedades Orbitales/diagnóstico , Enfermedades Orbitales/tratamiento farmacológico , Valor Predictivo de las Pruebas , Prednisolona/uso terapéutico , Resultado del Tratamiento
15.
Ophthalmologica ; 234(4): 227-32, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26368674

RESUMEN

BACKGROUND: Studies conducted in recent years have reported promising results regarding the treatment of retinoblastoma with the intra-arterial use of melphalan. In the present study, we intended to report the results of intra-arterial chemotherapy with melphalan (IACT) in the treatment of newly diagnosed or relapsed-refractory retinoblastoma patients at the Department of Pediatric Oncology of Hacettepe University, Ankara, Turkey. MATERIALS AND METHODS: This was a retrospective study of patients with intraocular retinoblastoma who were treated with IACT from December 2011 to May 2014. A total of 56 eyes of 46 consecutive patients (30 males and 16 females) were included in the study. Forty-four eyes received systemic chemotherapy upon diagnosis (systemic chemotherapy group, SCG), and 12 eyes were those of newly diagnosed patients (primary intra-arterial melphalan group, PIAG). The choice of the IACT dose was based on age. Tumor control and globe salvage with IACT were analyzed. Complete blood counts were examined 7 days after the IACT for systemic toxicity. Ocular toxicities such as proptosis, eyelid edema, ocular motility, and retinal and optic atrophy were assessed by an ocular oncologist with regular ophthalmologic examinations. RESULTS: Enucleation was avoided overall in 66% (37/56) of the eyes, including 75% (9/12) in the PIAG and 64% (28/44) in the SCG patients. The 1-year enucleation-free survival rate was 56.7% at a median follow-up time of 11.9 months (range 0.27-27.6). IACT was administered in a total of 124 cycles (ranging from 1 to 7 cycles, mean 2.3). The responses were as follows: regression of the retinal tumor in 27 eyes and improvements in vitreous seeding in 5 of 15 eyes. The further treatment requirements after IACT were as follows: enucleation in 19 eyes (10 with vitreous seeding), radiotherapy in 3 eyes, systemic chemotherapy in 1 eye, and local therapy in 1 eye. No severe systemic side effects occurred. Transient swelling of the eyelids (22 patients), conjunctival chemosis (12 patients), upper eyelid ptosis (5 patients), redness over the frontal area (3 patients), limitation of ocular motility (3 patients) and mild proptosis (1 patient) were detected. Retinal pigment epithelial alterations (30 patients) and optic atrophy (3 patients) were seen in the late follow-up. CONCLUSIONS: Globe salvage and avoidance of radiotherapy may be achieved by IACT with limited toxicity. This treatment is efficient, repeatable and safe.


Asunto(s)
Antineoplásicos Alquilantes/administración & dosificación , Melfalán/administración & dosificación , Recurrencia Local de Neoplasia/tratamiento farmacológico , Neoplasias de la Retina/tratamiento farmacológico , Retinoblastoma/tratamiento farmacológico , Antineoplásicos Alquilantes/uso terapéutico , Niño , Preescolar , Supervivencia sin Enfermedad , Enucleación del Ojo , Femenino , Humanos , Lactante , Infusiones Intraarteriales , Masculino , Melfalán/uso terapéutico , Neoplasias de la Retina/mortalidad , Neoplasias de la Retina/patología , Retinoblastoma/mortalidad , Retinoblastoma/patología , Estudios Retrospectivos , Tasa de Supervivencia
16.
Skeletal Radiol ; 44(4): 491-6, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25256752

RESUMEN

OBJECTIVE: Leukemia is a group of malignant diseases involving peripheral blood and bone marrow. Extramedullary tumor manifestation in leukemia can also occur. They more often involve lymph nodes, skin, and bones. Intramuscular leukemic relapse (ILR) is very unusual. The aim of this analysis was to summarize the reported data regarding clinical signs and radiological features of ILR. MATERIAL AND METHODS: The PubMed database was searched for publications related to ILR. After an analysis of all identified articles, 20 publications matched the inclusion criteria. The authors of the 20 publications were contacted and provided imaging of their cases for review. The following were recorded: age, gender, primary diagnosis, clinical signs, pattern, localization and size of the intramuscular leukemic relapse. Images of 16 patients were provided [8 computer tomographic (CT) images and 15 magnetic resonance images, MRI]. Furthermore, one patient with ILR was identified in our institutional database. Therefore, images of 17 patients were available for further analysis. RESULTS: Overall, 32 cases with ILR were included in the analysis. In most cases acute myeloid leukemia was diagnosed. Most ILRs were localized in the extremities (44 %) and in the extraocular muscles (44 %). Clinically, ILR manifested as local pain, swelling and muscle weakness. Radiologically, ILR presented most frequently with diffuse muscle infiltration. On postcontrast CT/MRI, most lesions demonstrated homogeneous enhancement. ILRs were hypo-/isointense on T1w and hyperintense on T2w images. CONCLUSION: ILR manifests commonly as focal pain, swelling and muscle weakness. ILR predominantly involved the extraocular musculature and the extremities. Radiologically, diffuse muscle infiltration was the most common imaging finding.


Asunto(s)
Leucemia/diagnóstico por imagen , Leucemia/patología , Imagen por Resonancia Magnética , Neoplasias de los Músculos/diagnóstico por imagen , Neoplasias de los Músculos/patología , Tomografía Computarizada por Rayos X , Adolescente , Adulto , Anciano , Niño , Preescolar , Medios de Contraste , Diagnóstico Diferencial , Femenino , Humanos , Lactante , Leucemia/terapia , Masculino , Persona de Mediana Edad , Neoplasias de los Músculos/terapia , Intensificación de Imagen Radiográfica , Recurrencia , Reproducibilidad de los Resultados , Estudios Retrospectivos , Adulto Joven
17.
Ophthalmic Plast Reconstr Surg ; 31(4): e91-3, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-24777267

RESUMEN

Renal carcinoid tumor is an exceedingly rare malignancy. A 57-year-old man with a renal carcinoid tumor discovered after metastasizing to intraocular and bilateral orbital structures is described. The patient presented with a blind painful OS and a right superotemporal subconjunctival mass. Imaging studies revealed a large left intraocular tumor, a mass in the left medial rectus muscle, and right lacrimal gland enlargement. The OS was enucleated, and incisional biopsies were performed from the other 2 lesions. Histopathological studies demonstrated metastatic neuroendocrine tumor with chromogranin and synaptophysin positivity. Systemic work up revealed a right renal mass and multiple hepatic metastatic lesions. Radical nephrectomy was performed, and octreotide, capecitabine, and temozolomide were administered. Removal of the primary tumor and the eye that had no prospect for useful vision and further treatment with octreotide, capecitabine, and temozolomide provided a disease progression-free period of 24 months and allowed the patient to function normally.


Asunto(s)
Tumor Carcinoide/secundario , Neoplasias Renales/patología , Enfermedades del Aparato Lagrimal/patología , Neoplasias de los Músculos/secundario , Músculos Oculomotores/patología , Neoplasias de la Úvea/secundario , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Biomarcadores de Tumor/metabolismo , Capecitabina/administración & dosificación , Tumor Carcinoide/metabolismo , Tumor Carcinoide/terapia , Cromogranina A/metabolismo , Terapia Combinada , Dacarbazina/administración & dosificación , Dacarbazina/análogos & derivados , Enucleación del Ojo , Neoplasias del Ojo/metabolismo , Neoplasias del Ojo/secundario , Neoplasias del Ojo/terapia , Humanos , Neoplasias Renales/metabolismo , Neoplasias Renales/terapia , Enfermedades del Aparato Lagrimal/metabolismo , Enfermedades del Aparato Lagrimal/terapia , Masculino , Persona de Mediana Edad , Neoplasias de los Músculos/metabolismo , Neoplasias de los Músculos/terapia , Nefrectomía , Octreótido/administración & dosificación , Sinaptofisina/metabolismo , Temozolomida , Neoplasias de la Úvea/metabolismo , Neoplasias de la Úvea/terapia
18.
Cornea ; 43(3): 391-393, 2024 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-38147572

RESUMEN

PURPOSE: The aim of this study was to describe a rare case of conjunctival black henna accumulation that was clinically misdiagnosed as melanoma. METHODS: This retrospective case report reviewed the clinical findings and histopathologic features of a pigmented plica semilunaris lesion excised from a 63-year-old woman. The patient had a history of regular use of black henna in her childhood. The conjunctival pigmentation was present since her early teenage years but started to grow only recently. RESULTS: There was a darkly pigmented mass mainly covering the plica semilunaris of the right eye with additional irregularly scattered pigmentation in the medial bulbar conjunctiva. Excisional biopsy of the plical tumor revealed nodular pigment deposits with lymphocytic infiltration. There were no neoplastic cells. The specimen stained negative for pan-keratin, CD68, and CD34. Melanin bleaching was also negative. CONCLUSIONS: Long-term exposure to black henna as a hair dye may lead to subconjunctival accumulation and mimic melanoma.


Asunto(s)
Enfermedades de la Conjuntiva , Neoplasias de la Conjuntiva , Melanoma , Fenilendiaminas , Femenino , Humanos , Persona de Mediana Edad , Conjuntiva/patología , Enfermedades de la Conjuntiva/diagnóstico , Neoplasias de la Conjuntiva/diagnóstico , Neoplasias de la Conjuntiva/patología , Melanoma/diagnóstico , Melanoma/patología , Estudios Retrospectivos
19.
Neurooncol Pract ; 11(2): 150-156, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38496921

RESUMEN

Background: Optic nerve sheath meningiomas (ONSM) are rare tumors potentially causing visual deficits. This study aims to report the anatomic and visual outcomes of patients with primary ONSM treated with hypofractionated stereotactic radiotherapy (HF-SRT). Methods: Data of 36 patients treated with HF-SRT between 2008 and 2019 were retrospectively collected. The clinical target volume (CTV) was equal to the gross tumor volume and a 2 mm was added for the planning target volume. All responses other than progression were accepted as local control (LC). The VA grading was performed under 3 groups to provide an even distribution; 20/400 or worse, 20/40-20/400, and 20/40 or better. Results: Median HF-SRT dose was 25 Gy and the median CTV was 1.94 cc. After a median of 106 months of follow-up, the tumor regressed in 23 (64%), was stable in 9 (25%), and progressed in 4 (11%) eyes. The overall rate of LC was 89% with 2-, 5-, 10-, and 15-year rate of 100%, 94%, 84%, and 84%, respectively. Treatment-related late toxicity rate was 11%. The VA was stable in 27 (75%) eyes, improved in 5 (14%) eyes, and worsened in 4 (11%) eyes, respectively, after HF-SRT. Female gender was the only independent predictor of an improved VA. Conclusions: Hypofractionated stereotactic radiotherapy is a safe and satisfactory treatment option for primary ONSM without severe toxicity. It may be advisable to commence treatment before an established visual deficit of 20/400 or worse occurs, to make the most of the functional benefit.

20.
Invest Ophthalmol Vis Sci ; 65(4): 12, 2024 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-38573618

RESUMEN

Purpose: To explore the genetic background of choroidal and ciliary body melanoma among children and young adults, with special focus on BAP1 germline variants in this age group. Methods: Patients under the age of 25 and with confirmed choroidal or ciliary body melanoma were included in this retrospective, multicenter observational study. Nuclear BAP1 immunopositivity was used to evaluate the presence of functional BAP1 in the tumor. Next-generation sequencing using Ion Torrent platform was used to determine pathogenic variants of BAP1, EIF1AX, SF3B1, GNAQ and GNA11 and chromosome 3 status in the tumor or in DNA extracted from blood or saliva. Survival was analyzed using Kaplan-Meier estimates. Results: The mean age at diagnosis was 17 years (range 5.0-24.8). A germline BAP1 pathogenic variant was identified in an 18-year-old patient, and a somatic variant, based mainly on immunohistochemistry, in 13 (42%) of 31 available specimens. One tumor had a somatic SF3B1 pathogenic variant. Disomy 3 and the absence of a BAP1 pathogenic variant in the tumor predicted the longest metastasis-free survival. Males showed longer metastasis-free survival than females (P = 0.018). Conclusions: We did not find a stronger-than-average BAP1 germline predisposition for choroidal and ciliary body melanoma among children and young adults compared to adults. Males had a more favorable survival and disomy 3, and the absence of a BAP1 mutation in the tumor tissue predicted the most favorable metastasis-free survival. A BAP1 germline pathogenic variant was identified in one patient (1%), and a somatic variant based mainly on immunohistochemistry in 13 (42%).


Asunto(s)
Melanoma , Neoplasias de la Úvea , Adolescente , Niño , Preescolar , Femenino , Humanos , Masculino , Adulto Joven , Cuerpo Ciliar , Melanoma/genética , Estudios Retrospectivos , Neoplasias de la Úvea/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA